{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-131920","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.310143+00:00","generated_at":"2026-06-02T22:08:55.594999+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation","bullets":["Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit","Net proceeds expected ~$30.2M; closing expected May 6, 2024","Common warrants exercisable at $3.50/share, expiring June 30, 2025","CEO and existing institutional investors participated in the offering","Proceeds to be used for working capital, R&D, and general corporate purposes"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-131920","json":"https://secwatch.observer/filing/0001193125-24-131920.json","markdown":"https://secwatch.observer/filing/0001193125-24-131920.md","text":"https://secwatch.observer/filing/0001193125-24-131920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/0001193125-24-131920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/d790042d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:08:55.594999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1128f3612e4ad90ab37e54f127557ce0eb8b09ea","claim":"Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the company\u0012s chief executive officer and certain of the company\u0012s existing institutional investors, including investors affiliated with certain of the company\u0012s directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).","evidence_excerpt":"On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/0001193125-24-131920-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named therein, including the company\u0012s chief executive officer and certain of the company\u0012s existing institutional investors, including investors affiliated with certain of the company\u0012s directors (collectively, the Investors )"},{"label":"Value","value":"combined offering price of $1.7312"},{"label":"Effective","value":"2024-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}